Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics (NASDAQ: ELTX) reported its Q1 2025 financial results and provided corporate updates. The company is advancing toward a crucial Phase 2 AMPLIFY-7P interim analysis expected in Q3 2025, focusing on disease-free survival in pancreatic cancer treatment. Key financial highlights include: R&D expenses of $7.8M (up from $7.6M in Q1 2024), G&A expenses of $3.0M (up from $2.7M), and a net loss of $11.2M ($0.87 per share). The company's cash position of $18.4M is expected to support operations into Q4 2025.
Notable developments include FDA alignment on key Phase 3 study design elements for ELI-002, appointment of Preetam Shah as Chief Strategy and Financial Officer, and a $10M registered direct offering. ELI-002 represents a potential breakthrough in treating mKRAS-driven tumors, particularly for pancreatic cancer patients with a 13% 5-year survival rate.
Elicio Therapeutics (NASDAQ: ELTX) ha comunicato i risultati finanziari del primo trimestre 2025 e fornito aggiornamenti aziendali. La società sta procedendo verso un'importante analisi intermedia di Fase 2 AMPLIFY-7P prevista per il terzo trimestre 2025, concentrandosi sulla sopravvivenza libera da malattia nel trattamento del cancro al pancreas. I principali dati finanziari includono: spese per R&S di 7,8 milioni di dollari (in aumento rispetto a 7,6 milioni nel primo trimestre 2024), spese generali e amministrative di 3,0 milioni di dollari (in aumento da 2,7 milioni), e una perdita netta di 11,2 milioni di dollari (0,87 dollari per azione). La liquidità disponibile di 18,4 milioni di dollari dovrebbe sostenere le operazioni fino al quarto trimestre 2025.
Tra gli sviluppi rilevanti vi sono l’allineamento con la FDA sugli elementi chiave del disegno dello studio di Fase 3 per ELI-002, la nomina di Preetam Shah come Chief Strategy and Financial Officer, e un’offerta diretta registrata da 10 milioni di dollari. ELI-002 rappresenta una potenziale svolta nel trattamento dei tumori guidati da mKRAS, in particolare per i pazienti con cancro al pancreas, che hanno un tasso di sopravvivenza a 5 anni del 13%.
Elicio Therapeutics (NASDAQ: ELTX) informó sus resultados financieros del primer trimestre de 2025 y proporcionó actualizaciones corporativas. La compañía avanza hacia un análisis intermedio crucial de Fase 2 AMPLIFY-7P esperado para el tercer trimestre de 2025, centrado en la supervivencia libre de enfermedad en el tratamiento del cáncer de páncreas. Los aspectos financieros clave incluyen: gastos en I+D de 7,8 millones de dólares (aumentando desde 7,6 millones en el primer trimestre de 2024), gastos generales y administrativos de 3,0 millones de dólares (subiendo desde 2,7 millones), y una pérdida neta de 11,2 millones de dólares (0,87 dólares por acción). La posición de efectivo de 18,4 millones de dólares se espera que respalde las operaciones hasta el cuarto trimestre de 2025.
Entre los desarrollos notables se encuentran la alineación con la FDA sobre elementos clave del diseño del estudio de Fase 3 para ELI-002, el nombramiento de Preetam Shah como Director de Estrategia y Finanzas, y una oferta directa registrada de 10 millones de dólares. ELI-002 representa un posible avance en el tratamiento de tumores impulsados por mKRAS, especialmente para pacientes con cáncer de páncreas, que tienen una tasa de supervivencia a 5 años del 13%.
Elicio Therapeutics (NASDAQ: ELTX)는 2025년 1분기 재무 결과를 발표하고 기업 업데이트를 제공했습니다. 회사는 췌장암 치료에서 무병 생존율에 중점을 둔 2025년 3분기 예정인 2상 AMPLIFY-7P 중간 분석을 향해 나아가고 있습니다. 주요 재무 하이라이트는 다음과 같습니다: 연구개발비 780만 달러(2024년 1분기 760만 달러에서 증가), 일반관리비 300만 달러(270만 달러에서 증가), 순손실 1,120만 달러(주당 0.87달러). 현금 보유액 1,840만 달러는 2025년 4분기까지 운영을 지원할 것으로 예상됩니다.
주목할 만한 발전 사항으로는 ELI-002 3상 시험 설계 주요 요소에 대한 FDA와의 조율, Preetam Shah의 최고전략재무책임자(CSFO) 임명, 1,000만 달러 규모의 등록 직접 공모가 포함됩니다. ELI-002는 특히 5년 생존율 13%인 췌장암 환자들을 위한 mKRAS 유발 종양 치료에 있어 잠재적인 혁신입니다.
Elicio Therapeutics (NASDAQ: ELTX) a publié ses résultats financiers du premier trimestre 2025 et fourni des mises à jour d'entreprise. La société progresse vers une analyse intermédiaire cruciale de la Phase 2 AMPLIFY-7P attendue au troisième trimestre 2025, axée sur la survie sans maladie dans le traitement du cancer du pancréas. Les points financiers clés comprennent : des dépenses en R&D de 7,8 millions de dollars (en hausse par rapport à 7,6 millions au T1 2024), des frais généraux et administratifs de 3,0 millions de dollars (en hausse par rapport à 2,7 millions), et une perte nette de 11,2 millions de dollars (0,87 dollar par action). La trésorerie de 18,4 millions de dollars devrait soutenir les opérations jusqu'au quatrième trimestre 2025.
Parmi les développements notables figurent l'alignement avec la FDA sur les éléments clés de la conception de l'étude de Phase 3 pour ELI-002, la nomination de Preetam Shah en tant que Chief Strategy and Financial Officer, et une offre directe enregistrée de 10 millions de dollars. ELI-002 représente une avancée potentielle dans le traitement des tumeurs à mKRAS, en particulier pour les patients atteints de cancer du pancréas, qui ont un taux de survie à 5 ans de 13 %.
Elicio Therapeutics (NASDAQ: ELTX) hat seine Finanzergebnisse für das erste Quartal 2025 veröffentlicht und Unternehmensupdates bereitgestellt. Das Unternehmen arbeitet auf eine entscheidende Zwischenanalyse der Phase 2 AMPLIFY-7P, erwartet im dritten Quartal 2025, hin, die sich auf das krankheitsfreie Überleben bei der Behandlung von Bauchspeicheldrüsenkrebs konzentriert. Wichtige finanzielle Eckdaten umfassen: F&E-Ausgaben von 7,8 Mio. USD (steigend von 7,6 Mio. USD im Q1 2024), Verwaltungs- und Gemeinkosten von 3,0 Mio. USD (steigend von 2,7 Mio. USD) sowie einen Nettoverlust von 11,2 Mio. USD (0,87 USD pro Aktie). Die Liquiditätsposition von 18,4 Mio. USD soll die Geschäftstätigkeit bis zum vierten Quartal 2025 unterstützen.
Bemerkenswerte Entwicklungen sind die Abstimmung mit der FDA zu wichtigen Designaspekten der Phase-3-Studie für ELI-002, die Ernennung von Preetam Shah zum Chief Strategy and Financial Officer sowie ein registriertes Direktangebot in Höhe von 10 Mio. USD. ELI-002 stellt einen potenziellen Durchbruch bei der Behandlung von mKRAS-getriebenen Tumoren dar, insbesondere für Patienten mit Bauchspeicheldrüsenkrebs, die eine 5-Jahres-Überlebensrate von 13 % haben.
- FDA alignment achieved on key Phase 3 study design elements for ELI-002
- Cash runway extended into Q4 2025, beyond critical Phase 2 interim analysis
- Successful $10M financing through registered direct offering
- Reduced net loss to $11.2M in Q1 2025 from $11.8M in Q1 2024
- Strengthened management team with appointment of new Chief Strategy and Financial Officer
- Increased R&D expenses by $0.2M compared to Q1 2024
- Higher G&A expenses, up $0.3M from previous year
- Operating loss increased to $10.7M from $10.2M in Q1 2024
Insights
Elicio's Phase 2 AMPLIFY-7P interim analysis expected in Q3 is a critical milestone for its novel mKRAS cancer immunotherapy platform.
Elicio's first quarter update highlights progress toward a crucial near-term catalyst - the Q3 2025 interim analysis of their Phase 2 AMPLIFY-7P trial evaluating ELI-002 in pancreatic cancer (PDAC). This disease-free survival (DFS) event-driven analysis represents a critical inflection point for validating their Amphiphile (AMP) platform technology.
The company has secured FDA alignment on key elements for a potential Phase 3 registrational trial, including dose, schedule, patient population, and DFS as the primary endpoint. This regulatory clarity significantly de-risks their clinical development pathway should Phase 2 data prove positive.
Financially, Elicio reported Q1 operating expenses of $10.7 million with $18.4 million in cash as of March 31. Their cash runway extends into Q4 2025, importantly carrying them beyond the upcoming interim analysis. The $10 million January financing has strengthened their position, though additional capital will likely be needed for advancing potential Phase 3 studies.
What makes ELI-002 particularly interesting is its off-the-shelf approach targeting mKRAS mutations, which drive approximately 25% of solid tumors. This contrasts with personalized cancer vaccines and could enable faster manufacturing, lower costs, and broader availability. The technology's potential extends beyond pancreatic cancer to colorectal, lung, and other mKRAS-driven cancers.
The Q3 interim analysis will be watched closely as positive DFS data could validate not just ELI-002 but their entire platform, creating significant value across their pipeline which includes additional cancer vaccine candidates ELI-007 and ELI-008 targeting BRAF mutations and p53 hotspot mutations respectively.
Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025
Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements of planned Phase 3 study of ELI-002
Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis
BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate and clinical updates.
“In the first quarter, we made continued progress toward our upcoming Phase 2 AMPLIFY-7P event-driven interim analysis, expected next quarter—a key milestone for Elicio and for patients facing pancreatic ductal adenocarcinoma (“PDAC”),” said Robert Connelly, Chief Executive Officer of Elicio. “We believe ELI-002 represents a potentially transformative approach in the treatment of mKRAS-driven tumors, and the upcoming randomized interim data readout in PDAC will be a critical validating opportunity for our AMP platform. To this end, we believe the upcoming results could demonstrate ELI-002’s impact not only in PDAC—a particularly difficult-to-treat cancer with a 5-year survival rate of
Recent Highlights
- In March 2025, Elicio appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer.
- In January 2025, Elicio strengthened its cash position with a
$10.0 million registered direct offering of common stock and warrants. - In January 2025, Elicio reached alignment with regulatory authorities on a registrational strategy for ELI-002 in post-resection (adjuvant setting) mKRAS PDAC. Specifically, Elicio aligned with the FDA on key elements of a planned Phase 3 study design—including dose, schedule, patient population and primary endpoint analysis based on DFS.
Upcoming Anticipated Milestones
- DFS event-driven interim analysis of Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025.
- Potential to finalize pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in H2 2025.
First Quarter 2025 Financial Results
R&D expense for the first quarter of 2025 was
G&A expense for the first quarter of 2025 was
Net loss for the first quarter of 2025 was
Cash and cash equivalents, as of March 31, 2025, were
The Company expects that its current cash and cash equivalents will support operations into Q4 2025, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis.
| ELICIO THERAPEUTICS, INC. | ||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| (unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 7,778 | $ | 7,559 | ||||
| General and administrative | 2,958 | 2,682 | ||||||
| Total operating expenses | 10,736 | 10,241 | ||||||
| Loss from operations | (10,736 | ) | (10,241 | ) | ||||
| Total other (expense) income, net | (473 | ) | (1,586 | ) | ||||
| Net loss | (11,209 | ) | (11,827 | ) | ||||
| Other comprehensive gain (loss): | ||||||||
| Foreign currency translation adjustment | 31 | (73 | ) | |||||
| Comprehensive loss | $ | (11,178 | ) | $ | (11,900 | ) | ||
| Net loss per common share, basic and diluted | $ | (0.87 | ) | $ | (1.15 | ) | ||
| Weighted average common shares and pre-funded warrants outstanding, basic and diluted | 12,950,574 | 10,273,925 | ||||||
| ELICIO THERAPEUTICS, INC. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (in thousands) | ||||||||
| (unaudited) | ||||||||
| March 31, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 18,351 | $ | 17,618 | ||||
| Other current assets | 2,584 | 3,075 | ||||||
| Total current assets | 20,935 | 20,693 | ||||||
| Other assets | 7,209 | 7,485 | ||||||
| Total assets | $ | 28,144 | $ | 28,178 | ||||
| Liabilities and stockholders' (deficit) equity | ||||||||
| Current liabilities | $ | 11,413 | $ | 11,523 | ||||
| Long-term liabilities | 7,827 | 27,967 | ||||||
| Total liabilities | 19,240 | 39,490 | ||||||
| Total stockholders' (deficit) equity | 8,904 | (11,312 | ) | |||||
| Total liabilities and stockholders' (deficit) equity | $ | 28,144 | $ | 28,178 | ||||
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer vaccine space to develop effective, off-the-shelf vaccines. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional vaccination strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately
About ELI-002
Elicio’s lead product candidate, ELI-002, is a structurally novel investigational AMP cancer vaccine that targets cancers that are driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio’s AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration.
ELI-002 2P (2-peptide formulation) has been studied in the Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy (NCT04853017). ELI-002 7P (7-peptide formulation) is currently being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer (NCT05726864). The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in
About the Amphiphile Platform
Elicio’s proprietary AMP platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes its AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based on preclinical studies.
Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships.
The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the local injection site, as it travels to lymphatic tissue.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding the sufficiency of Elicio’s existing cash and cash equivalents to support operations into the fourth quarter of 2025, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis; expectations about Elicio’s financial and operating results; Elicio’s planned clinical programs, including the timing and outcome of planned clinical trials and the potential to finalize pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in the second half of 2025; the timing of the expected interim analysis of the Phase 2 AMPLIFY-7P clinical trial; the potential of Elicio’s product candidates, including the potential transformational approach ELI-002 could represent in the treatment of mKRAS-driven tumors; the potential impact of ELI-002 in PDAC, the momentum the upcoming Phase 2 AMPLIFY-7P interim analysis could provide for broader application of Elicio’s technology across additional indications and the potential for Elicio’s Phase 2 AMPLIFY-7P interim analysis to be a critical validating opportunity for Elicio’s AMP platform; the potential for future expansion of ELI-002 to other indications; the potential benefits and effectiveness of off-the-shelf vaccine approaches; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s financial condition, including its anticipated cash runway, and ability to obtain the funding necessary to advance the development of ELI-002 and any other future product candidates, and Elicio’s ability to continue as a going concern; Elicio’s plans to develop and commercialize its product candidates, including ELI-002; the timing of initiation of Elicio’s planned clinical trials; the timing of the availability of data from Elicio’s clinical trials, including the DFS event-driven interim analysis, from the Phase 2 AMPLIFY-7P trial expected in the third quarter of 2025; the timing of any planned investigational new drug application or new drug application; Elicio’s plans to research, develop and commercialize its current and future product candidates; and Elicio’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.
New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks are more fully discussed in the Annual Report on Form 10-K filed with the SEC on March 31, 2025, under the heading “Risk Factors” and any subsequent reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.
Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
FAQ
What were Elicio Therapeutics (ELTX) key financial results for Q1 2025?
When is Elicio's Phase 2 AMPLIFY-7P interim analysis expected?
How long will Elicio's current cash position support operations?
What is the status of Elicio's ELI-002 FDA approval process?
What recent corporate changes has Elicio Therapeutics made?
